TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2017

CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.

Jatinder K Lamba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.